LON:SUMM

Summit Therapeutics (SUMM) Share Price, News & Analysis

Today's Range
N/A
50-Day Range
20.50
20.50
52-Week Range
N/A
Volume
280,318 shs
Average Volume
382,504 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
SUMM stock logo

About Summit Therapeutics Stock (LON:SUMM)

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.

SUMM Stock News Headlines

Q1 2024 Summit Therapeutics Inc Earnings Call
Could Your Accounts Be Frozen?
The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.
Could Your Accounts Be Frozen?
The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.
2024 DTA Summit Agenda is LIVE!!
Coave Therapeutics to Present at Upcoming Conferences
See More Headlines
Receive SUMM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
6/12/2019
Today
5/05/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drugs - Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Glyn O. Edwards (Age 63)
    CEO & Exec. Director
  • Mr. Erik Ostrowski (Age 46)
    Chief Financial Officer
  • Prof. David Roblin (Age 53)
    COO, Chief Medical Officer and Pres of R&D
  • Prof. Kay Davies (Age 69)
    Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor
  • Ms. Michelle Avery
    Director of Investor Relations

SUMM Stock Analysis - Frequently Asked Questions

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics PLC (LON:SUMM) posted its quarterly earnings data on Wednesday, June, 12th. The company reported ($3.00) EPS for the quarter, beating the consensus estimate of ($4.00) by $1.00.

What other stocks do shareholders of Summit Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include Summit Therapeutics (SMMT), American Airlines Group (AAL), Acadia Healthcare (ACHC), Diana Shipping (DSX), 2570 (JLF.L) (JLF), National Fuel Gas (NFG), Tailored Brands (TLRD), The Weir Group (WEIR) and Acacia Mining (ABGLF).

How do I buy shares of Summit Therapeutics?

Shares of SUMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:SUMM) was last updated on 5/5/2024 by MarketBeat.com Staff

From Our Partners